通讯作者: 牛晓珊, 470097414@qq.com

DOI：10.12201/bmr.202410.00006

Advances in pharmacological studies of NF-κB involved in the regulation of nonalcoholic fatty liver disease

• 摘要：非酒精性脂肪肝病(non-alcoholic fatty liver disease,NAFLD)是一种慢性代谢性疾病，是我国慢性肝病的常见原因之一，其发病机制复杂多样，可能受到胰岛素抵抗、内源性损害因子、遗传因素、氧化应激、肠道菌群失衡和环境及饮食因素的多重影响。NF-κB在代谢、氧化、免疫和炎症反应之间具有重要的分子联系，在NAFLD患者和NAFLD动物模型中激活程度高。近年来针对NF-κB转录因子的相关药物研究越来越受到重视，因此本文从现有的NAFLD相关药物研究角度出发，重点叙述了目前有望成为NAFLD的治疗药物的作用机制，以及NF-κB是否参与调控此类药物对NAFLD发生发展的影响。目前的药物研究中，维生素E、吡格列酮、阿托伐他汀以及一些传统中草药均有望成为NAFLD的治疗用药，且NF-κB在其中可能发挥重要作用。但目前对于NAFLD的药物治疗机制大多停留在表面，且部分药物仅停留在理论阶段，尚缺乏大量临床数据进行支撑。未来可以进一步挖掘NF-κB在NAFLD发病过程中的作用机制以及相关基因调控位点，从而为个体免受NAFLD提供预防和治疗潜力。

  关键词： 非酒精性脂肪性肝病；NF-κB；炎症；胰岛素抵抗；中草药

   

  Abstract: Non-alcoholic fatty liver disease (NAFLD) is a chronic metabolic disease and one of the common causes of chronic liver disease in China. Its pathogenesis is complex and varied, and it may be affected by multiple influences of insulin resistance, endogenous damaging factors, genetic factors, oxidative stress, intestinal flora imbalance and environmental and dietary factors. NF-κB has important molecular links between metabolic, oxidative, immune and inflammatory responses and is highly activated in NAFLD patients and NAFLD animal models. Drug studies related to NF-κB transcription factors have received increasing attention in recent years, so this article focuses on the mechanism of action of currently promising therapeutic drugs for NAFLD from the perspective of existing NAFLD-related drug studies and whether NF-κB is involved in modulating the effects of such drugs on the development of NAFLD. In current drug studies, vitamin E, pioglitazone, atorvastatin, and some traditional Chinese herbs are expected to be therapeutic drugs for NAFLD, and NF-κB may play an important role in them. However, most of the current drug treatment mechanisms for NAFLD remain on the surface, and some of the drugs are only in the theoretical stage, lacking a large amount of clinical data to support. In the future, we can further explore the mechanism of NF-κB in the pathogenesis of NAFLD as well as the related gene regulatory sites, so as to provide the potential of prevention and treatment for individuals against NAFLD.

  Key words: Non-alcoholic Fatty Liver Disease；NF-kappa B；Inflammation；Insulin Resistance；Drugs, Chinese Herbal

  提交时间：2024-10-05

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 张丽霞, 郎泽高, 王辉. PD患者SIRT1/NF-κB信号通路与认知功能损害的相关性. 2024. doi: 10.12201/bmr.202412.00077

  贾晨, 巩 艳, 韩懿晶, 姜佳楠, 刘唯正, 张大旭, 吕文平. 心理压力与代谢相关脂肪性肝病的相关性研究. 2022. doi: 10.12201/bmr.202204.00003

  杜明斗. 体力活动-胰岛素敏感性因果关系研究. 2022. doi: 10.12201/bmr.202210.00027

  郭慧芳, 沈沛成. 慢性肾脏病中医非药物疗法研究概述. 2024. doi: 10.12201/bmr.202409.00054

  高春柳, 张晗, 褚梦圆, 许凯凯, 项馨, 闫颖. Isthmin1蛋白在多囊卵巢综合征中作用机制的进展. 2024. doi: 10.12201/bmr.202411.00004

  陈书逸, 何飞. “保胃气”在辨治非结核分枝杆菌肺病的应用. 2024. doi: 10.12201/bmr.202407.00002

  刘迷迷, 杜国霞, 周毅, 吴斌, 吴晓瑛. 肝硬化专病数据库建设与应用研究. 2021. doi: 10.12201/bmr.202104.00014

  侯靖诗, 杨晓东. PHLDA3在疾病中的研究进展. 2024. doi: 10.12201/bmr.202407.00029

  徐建杭, 刘亚楠, 詹明, 韩飞. 非奈利酮治疗糖尿病肾病的研究进展与展望. 2024. doi: 10.12201/bmr.202410.00033

  钱蒙蒙, 郭潇辰, 王鹏飞, 陈秀, 伍欣尧, 邹春鹏, 徐茂晟. SWE在MAFLD早期肝脏及肾脏纤维化中的应用价值. 2024. doi: 10.12201/bmr.202409.00010

• 序号	提交日期	编号	操作
  1	2024-08-29	bmr.202410.00006V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论